bullish

Yichang HEC Changjiang Pharma

HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth

HEC Pharma’s revenue jumped ~6x in 1H22, driven by volume recovery of its core drug Kewei. Going ahead, new generic launches and insulin portfolio should accelerate the company’s growth trajectory.

Equity Bottom-Up
301 Views, 27 Nov 2022 05:15
SUMMARY
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now

Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth
    27 Nov 2022
  • Yichang HEC Changjiang Pharma (1558 HK): Multiple New Products Launches Bring New Opportunities
    24 Nov 2021
x